P135 Efficacy and safety of upadacitinib in TNFi inadequate responders with rheumatoid arthritis from three Phase 3 clinical trials

Abstract Background/Aims For patients with RA who are refractory to biologic disease-modifying antirheumatic drugs (bDMARDs), such as tumor necrosis factor inhibitors (TNFis), optimal disease control is less likely to be achieved with subsequent therapy. In line with recommendations from EULAR and A...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Rheumatology (Oxford, England) England), 2023-04, Vol.62 (Supplement_2)
Hauptverfasser:	Fleischmann, Roy, Bessette, Louis, Hall, Stephen, Sparks, Jeffrey, Jain, Manish, Kakehasi, Adriana, Song, Yanna, Meerwein, Sebastian, DeMasi, Ryan, Suboticki, Jessica, Rubbert-Roth, Andrea
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!